Abstract
Objective: To compare the direct healthcare costs of patients with congestive heart failure (CHF) prescribed torasemide (torsemide) or furosemide (frusemide).
Design and setting: As part of a prospective, randomised, nonblind study, we assessed the effects of torasemide and furosemide on readmission to hospital in 193 patients treated for CHF at a US urban public healthcare system. We also calculated total direct healthcare costs for the 2 drugs. The perspective of the analysis was that of the healthcare system. Healthcare charge and utilisation data, demographic information, and health status data were obtained from an electronic database containing data for all patients treated within the healthcare system.
Patients and participants: Upon admission to the hospital, patients were eligible if they had evidence of left ventricular systolic dysfunction, were at least 18 years old, and were receiving furosemide.
Intervention: Inpatients were randomised to either torasemide or furosemide treatment for 1 year.
Main outcomemeasures and results: Patients treated with torasemide had fewer hospital admissions than those treated with furosemide [18 vs 34% for CHF (p = 0.013) and 38 vs 58% for any cardiovascular cause (p = 0.005)]. In the torasemide group, expected annual hospital costs per patient were lower for CHF admissions (by $US1054; 1998 values) and for all cardiovascular admissions (by $US1545) than in the furosemide group. Because the annual acquisition cost of torasemide was $US518 per patient higher than that of furosemide, the resulting net cost saving per patient was $US536 for CHF and $US1027 for all cardiovascular causes. Outpatient costs did not differ between treatment groups regardless of whether drug costs were considered. Total direct costs were $US2124 lower with torasemide than with furosemide (not statistically significant).
Conclusions: Owing largely to reduced readmission to the hospital, the cost of inpatient care for patients with CHF is significantly lower with torasemide than with furosemide, despite the higher acquisition cost of torasemide. Treatment with torasemide resulted in a nonsignificant reduction in total direct costs (outpatient plus inpatient) compared with furosemide.
Similar content being viewed by others
References
American Heart Association. 1999 Heart and Stroke Statistical Update. Dallas (TX): American Heart Association, 1999
National Heart, Lung, and Blood Institute. Morbidity and Mortality Chartbook on Cardiovascular, Lung, and Blood Diseases, 1996. Bethesda (MD): US Department of Health and Human Services, 1996
Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973–1986: evidence for increasing population prevalence. Arch Intern Med 1990; 159: 769–73
Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999; 159: 29–34
Rich MW. Heart failure disease management: a critical review. J Card Fail 1999; 5: 64–75
Andrews R, Cowley AJ. Clinical and economic factors in the treatment of congestive heart failure. Pharmacoeconomics 1995; 7: 119–27
Haldeman GA, Croft JB, Giles WH, et al. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999; 137: 352–60
Bennett SJ, Huster GA, Baker SL, et al. Characterization of the precipitants of hospitalization for heart failure decompensation. Am J Crit Care 1998; 7: 168–74
Krück F. Acute and long-term effects of loop diuretics in heart failure. Drugs 1991; 41 Suppl. 3: 60–8
Dunn CJ, Fitton A, Brogden RN. Torasemide: an update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49 (1): 121–2
Vargo D, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995; 57: 601–9
Murray MD, Haag KM, Black PK, et al. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy 1997; 17: 98–106
Murray MD, Tierney WM, Brater DC. Determining the effectiveness of torsemide and furosemide in heart failure: design of a randomized comparison using the Regenstrief Medical Record System. Clin Drug Invest 1998; 16: 45–52
McDonald CJ, Tierney WM, Overhage JM, et al. The Regenstrief Medical Record System: 20 years of experience in hospitals, clinics, and neighbourhood health centers. MD Comput 1992; 9: 206–17
Murray MD, Loos B, Tu W, et al. Effect on pharmacist work patterns of on-line prescription order entry. J Am Med Inform Assoc 1998; 5: 546–53
American Medical Association. Medicare RBRVS: the physicians’ guide. Chicago (IL): American Medical Association,1993
Tu W, Zhou XH. A Wald test for the mean equality for log-normal data containing zero values. Stat Med 1999; 18: 2749–61
Greene WH. Econometric analysis. NewYork (NY): Macmillan Publishing Company, 1993
Tierney WM, Miller ME, McDonald CJ. The effect on test ordering of informing physicians of the charges for outpatient diagnostic tests. N Engl J Med 1990; 322: 1499–504
Heaton AH, Bryant J, Berman BJ, el al. Pharmacoeconomic comparison of loop diuretics in the treatment of congestive heart failure. Med Interface 1996; 9: 101–7
Murray MD, Forthofer MM, Bennett SJ, et al. Effectiveness of torasemide and furosemide in the treatment of CHF: results of a prospective, randomized trial [abstract 1568]. Circulation 1999; 1000: I–3000
Rich MW, Nease RG. Cost-effectiveness analysis in clinical practice: the case of heart failure. Arch Intern Med 1999; 159: 1690–700
CIBIS-II Investigators and Committee. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 1999; 353: 9–13
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–17
Gage LS. The future of safety-net hospitals. In the future U.S. healthcare system: who will care for the poor and uninsured? Chicago (IL): Health Administration Press, 1998: 123–49
Acknowledgements
The authors would like to thank Ms Faye Smith and Marina Weisburd for their technical contributions to this study. We also thank Xiao-Hua Zhou, Ph.D. for reviewing a draft version of the manuscript. Funding for this study was provided by NIH R01 DK 37993 and AG07631, and by Roche Laboratories.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stroupe, K.T., Forthofer, M.M., Brater, D.C. et al. Healthcare Costs of Patients with Heart Failure Treated with Torasemide or Furosemide. Pharmacoeconomics 17, 429–440 (2000). https://doi.org/10.2165/00019053-200017050-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200017050-00002